The efficacy of inspiring carbogen and low concentration oxygen combined with late course accelerated hyperfraction radiotherapy on esophageal carcinoma
10.3760/cma.j.issn.1008-6706.2009.03.010
- VernacularTitle:吸入高低氧联合后程加速超分割放疗对食管癌的疗效探讨
- Author:
Yanwei SUN
;
Jiayun ZHOU
;
Yongheng AN
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Oxygen inhalation therapy;
Radiotherapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2009;16(3):402-404
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of inspiring carbogen and low concentration oxygen combined with late coupe accelerated hyperfraction radiotherapy on esophageal carcinoma.Methods 74 patients with esophageal carcinoma were randomly divided into two groups:the trial group and the centrol group,which consisted of 37 patients respectively.6MV X-ray was employed in the two groups.The schedule of the trial group was as following:conventional radiotherapy of 1.8～2.0Gy per day was employed during the first phase to a total dose of 38～40Gy,followed by late course accelerated hyperfraetion radiotherapy(twice fractions per day,interval between two fractions more than 6 hours,1.3～1.4Gy per fraction,middle total dose of 64.2Gy).Carbogen and low concentraetion oxygen was inspired during the course of radiation.Results 71 patients were enrolled.At the end of radiation at a total dose of 38～40Gy,complete remission rate(CRR)in the trial group was 31%,whereas that in the control group was 19%(P＞0.05),when the whole radiotherapy was finished,the CRR was 57%and 31%(P＜0.05)respectively,and one month after radiotherapy.the CRR was 71%and 33%respectively(P＜0.01).Six months after radiotherapy,the CRR WaLa 74%and 36%respectively(P＜0.01).Thelocal controlrate of sixmonthswas 91% and 72% respectively in the two groups(P＜0.05).Conclusions Inspiring carbogen and low concentration oxygen combined with late course accelerated hyperfraction radiotherapy may sigllificantly improve short-term efficacy and local control rate in esophageal carcinoma patients in Ⅰ～Ⅲstage.Furthermore,its side effects can be tolerated,and its elongating life time of patients may be prognostic.
